MedPath

Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis

Phase 1
Conditions
Ulcerative Colitis
Mesenchymal Stem Cells
Umbilical Cord
Interventions
Biological: Umbilical Cord Mesenchymal Stem Cells
Registration Number
NCT01221428
Lead Sponsor
Qingdao University
Brief Summary

The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of treatment for ulcerative colitis is safe and effective.

Detailed Description

Ulcerative colitis is characterized as chronic and nonspecific inflammation of gastroenteritis tract.Nowadays,etiology and pathogenesis of UC have been unclear.Recent basic research has been revealed that stem cell can settle down in epithelium of gastroenteritis tract,which provide a hope for treating the disease.We hope umbilical cord Mesenchymal Stem Cells could not only address the need for epithelial cell replacement but also control of the autoimmune response to mocous membrane of colon.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Male or female, 18 years of age or older.
  • Ulcerative colitis described according to usual criteria.
  • Refractoriness Ulcerative colitis or unefficient by using other therapy
  • Signed informed consent form.
Exclusion Criteria
  • History of neoplasm or hematological disease
  • Uncontrolled high blood pressure (>180/110)
  • Severe cardiac insufficiency (New York Heart Association [NYHA] IV) or ejection fraction<30%
  • Malignant ventricular arrythmia
  • Deep venous thrombosis during the last 3 months
  • Active bacterial infection
  • Body mass index > 35 Kg/m2
  • Stroke or myocardial infarction during the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
umbilical cord mesenchymal stem cellsUmbilical Cord Mesenchymal Stem CellsIntravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
Primary Outcome Measures
NameTimeMethod
the result of enteroscopy and pathological report3 months
Secondary Outcome Measures
NameTimeMethod
the clinical symptom (including stomachache,abdominal distention,bloody purulent stool)3 months

Trial Locations

Locations (1)

Stem Cell Research Center of Medical School Hospital of Qingdao University

🇨🇳

Qingdao, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath